Professor Michael Barry:

About that. I will say one thing in relation to it and a point I made earlier. Only one drug satisfied the cost-effectiveness threshold of the orphan drugs we looked at this year, but we have reimbursed 12. If you are negotiating on very expensive drugs, the question is where you are negotiating to. What is the price? The assessment indicates to the HSE what price you would like to get it at. That is what the negotiations do. Even though one satisfied the criteria, 12 were reimbursed. Do you know what I mean? It does not-----